secwatch.observer — SEC 8-K summary
======================================

Issuer:     Passage BIO, Inc. (PASG)
CIK:        0001787297
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001104659-26-002696
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Passage Bio reports preliminary cash ~$46M as of Dec 31, 2025; runway into Q1 2027
--------------------------------------------------------------------------------

- Preliminary unaudited cash, cash equivalents and marketable securities of approximately $46 million as of December 31, 2025.
- Company expects the cash position to fund operating expenses and capital expenditures into the first quarter of 2027.
- Amount is preliminary, subject to completion of year-end financial review, adjustments, and audit.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787297/000110465926002696/0001104659-26-002696-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787297/000110465926002696/tm262847d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-002696

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer